Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James

Courtesy of Benzinga.

Near-Term Catalysts, Long-Term Opportunities Make Quidel A Strong Buy, Says Raymond James

Diagnostic healthcare products manufacturer Quidel Corporation (NASDAQ: QDEL)’s shares are not fully reflecting the company’s growth potential and likely positive estimate revision bias, according to Raymond James. 

The Analyst

Raymond James analyst Nicholas Jansen upgraded shares of Quidel from Outperform to Strong Buy and increased the price target from $55 to $69.

The Thesis

After meetings with Quidel management at the 39th Annual Raymond James Institutional Investors Conference, Jansen said he identified the following as near-term catalysts and long-term opportunities. 

Near-Term Catalysts

  • Strong Q1 results: A better-than-thought Q1 flu season and strength in Sofia 2 and Solana placements are likely to help the company achieve revenue growth of 25 percent in Q1 compared to earlier expectations of 10-15 percent growth, the analyst said. Quidel’s reference to its adjusted EBITA guidance as the “baseline” in the event of a normal flu season, suggesting likely upside, Jansen said.
  • Analyst day scheduled for April: Raymond James expects Quidel will provide a long-term product roadmap and go deeper into its growth drivers at the event, which could serve as a catalyst.

Long-Term Opportunities

  • The underappreciated installed base growth for the Sofia and Solana diagnostic testing platforms is becoming more valuable as the test menu expands
  • Raymond James said it has has increasing confidence in the Triage integration and additional revenue and cost synergy opportunities.
  • A long-term opportunity exists to cross-sell Quidel’s product suite into new global commercial infrastructure, and the company has the potential for additional tuck-in M&A.

The Price Action

Quidel shares are up about 124 percent over the past year.

The stock was surging 4.59 percent to $49.03 at the time of publication Thursday afternoon. 

Related Links:

Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges

7 Biotech Stocks With Clinical Trial Outcomes In March

Latest Ratings for QDEL

Date Firm Action From To
Mar 2018 Raymond James Upgrades Outperform Strong Buy
Jan 2018 CL King Upgrades Neutral Buy
Nov 2017 Barclays Maintains Overweight

View More Analyst Ratings for QDEL


View the Latest Analyst Ratings

Posted-In: flu influenzaAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!